# Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)

> **NCT01106287** · PHASE1 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 13 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** MK-0941
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT01106287
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-03
- **Target enrollment:** 13 (ACTUAL)
- **Last updated:** 2016-02-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01106287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01106287, "Single Doses of MK-0941 in Type 2 Diabetics (MK-0941-027)". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01106287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*